Pfizer Long Term Debt 2012-2026 | PFE
Pfizer long term debt from 2012 to 2026. Long term debt can be defined as the sum of all long term debt fields.
- Pfizer long term debt for the quarter ending March 31, 2026 was $57.409B, a 1.02% decline year-over-year.
- Pfizer long term debt for 2024 was $57.405B, a 6.72% decline from 2023.
- Pfizer long term debt for 2023 was $61.538B, a 87.14% increase from 2022.
- Pfizer long term debt for 2022 was $32.884B, a 9.15% decline from 2021.
|
Pfizer Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $57,405 |
| 2023 | $61,538 |
| 2022 | $32,884 |
| 2021 | $36,195 |
| 2020 | $37,133 |
| 2019 | $35,955 |
| 2018 | $32,909 |
| 2017 | $33,538 |
| 2016 | $31,398 |
| 2015 | $28,740 |
| 2014 | $31,541 |
| 2013 | $30,462 |
| 2012 | $31,036 |
| 2011 | $34,926 |
|
Pfizer Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-09-30 | $57,409 |
| 2025-06-30 | $57,502 |
| 2025-03-31 | $57,639 |
| 2024-12-31 | $57,405 |
| 2024-09-30 | $58,002 |
| 2024-06-30 | $57,506 |
| 2024-03-31 | $61,307 |
| 2023-12-31 | $61,538 |
| 2023-09-30 | $61,048 |
| 2023-06-30 | $61,356 |
| 2023-03-31 | $31,704 |
| 2022-12-31 | $32,884 |
| 2022-09-30 | $32,629 |
| 2022-06-30 | $34,294 |
| 2022-03-31 | $35,656 |
| 2021-12-31 | $36,195 |
| 2021-09-30 | $36,250 |
| 2021-06-30 | $35,354 |
| 2021-03-31 | $35,347 |
| 2020-12-31 | $37,133 |
| 2020-09-30 | $49,785 |
| 2020-06-30 | $50,529 |
| 2020-03-31 | $36,281 |
| 2019-12-31 | $35,955 |
| 2019-09-30 | $36,044 |
| 2019-06-30 | $36,168 |
| 2019-03-31 | $35,733 |
| 2018-12-31 | $32,909 |
| 2018-09-30 | $33,652 |
| 2018-06-30 | $28,935 |
| 2018-03-31 | $31,831 |
| 2017-12-31 | $33,538 |
| 2017-09-30 | $34,503 |
| 2017-06-30 | $34,191 |
| 2017-03-31 | $36,330 |
| 2016-12-31 | $31,398 |
| 2016-09-30 | $30,437 |
| 2016-06-30 | $30,457 |
| 2016-03-31 | $27,824 |
| 2015-12-31 | $28,740 |
| 2015-09-30 | $29,079 |
| 2015-06-30 | $26,729 |
| 2015-03-31 | $29,370 |
| 2014-12-31 | $31,541 |
| 2014-09-30 | $31,666 |
| 2014-06-30 | $32,267 |
| 2014-03-31 | $27,649 |
| 2013-12-31 | $30,462 |
| 2013-09-30 | $31,812 |
| 2013-06-30 | $31,532 |
| 2013-03-31 | $31,481 |
| 2012-12-31 | $31,036 |
| 2012-09-30 | $31,083 |
| 2012-06-30 | $30,868 |
| 2012-03-31 | $33,543 |
| 2011-12-31 | $34,926 |
| 2011-09-30 | $35,399 |
| 2011-06-30 | $35,723 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |